Constellation Pharmaceuticals has secured Series B additional venture financing worth $15 million. Investors that participated in the round include Third Rock Ventures, Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.
The biopharmaceutical company will use the proceeds from the financing to continue to advance product candidates in its portfolio towards clinical development. The recent funding brings the firm’s total second round of fundraising to $37 million, adds Business Journal.
Click here for the release from Business Wire.
Click here for additional coverage from Business Journal.